KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.

Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC